CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Telmisartan 20mg +2 moredrug
Likely dose
Telmisartan 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02471833
NCT02471833Phase 2Completed
CompareCT.gov

Health Evaluation in African Americans Using RAS Therapy

Emory University·interventional·Posted Jun 15, 2015·Updated May 23, 2024

In Brief

A Phase 2 clinical trial evaluating Telmisartan 20mg, Telmisartan 40mg, and 1 other intervention for Alzheimer's Disease. Completed, enrolled 61 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if telmisartan, an FDA approved blood pressure medication, may also have beneficial effects on Alzheimer's disease prevention in African Americans, who are at high risk for Alzheimer's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 15, 2015
Enrollment StartApr 1, 2015
Primary CompletionApr 15, 2022
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 11.0 years ago

Interventions

Telmisartan 20mgdrug

Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

Telmisartan 40mgdrug

Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

Placebodrug

Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.